--- title: "3 Australian Stocks With Stronger Balance Sheets And Earnings Growth" type: "News" locale: "en" url: "https://longbridge.com/en/news/290347152.md" description: "The article highlights three Australian stocks—DroneShield, IperionX, and Sigma Healthcare—selected for their strong balance sheets and earnings growth potential. DroneShield benefits from repeat defense contracts despite transition risks. IperionX offers critical minerals exposure but faces funding and execution challenges. Sigma Healthcare shows steady revenue growth but deals with compressed margins and high valuation multiples." datetime: "2026-06-21T10:58:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290347152.md) - [en](https://longbridge.com/en/news/290347152.md) - [zh-HK](https://longbridge.com/zh-HK/news/290347152.md) generator: "portal-rs" --- # 3 Australian Stocks With Stronger Balance Sheets And Earnings Growth Penny stocks often attract attention for their low share prices, but the real opportunity can lie in finding companies with healthier balance sheets and cleaner cash flows than the typical early stage stock. With inflation, interest rates and energy costs all pulling markets in different directions, many investors are looking for ways to target potential growth while trying to keep a closer eye on risk. This is where the Financially Fit Penny Stocks screener comes in. It focuses on lower priced stocks that meet basic financial quality checks. Below, you will see 3 stocks from this screener that stand out on these criteria. ## DroneShield (ASX:DRO) **Overview:** DroneShield is a Sydney based defence technology company that develops and sells counter drone hardware and software platforms used to detect and disrupt unmanned aerial threats for military, government, and critical infrastructure customers worldwide. Its product range spans wearable detectors, handheld countermeasure devices, fixed site systems, and command and control software tailored for both tactical and large scale security operations. **Operations:** DroneShield currently generates all of its A$216.8 million in revenue from the Aerospace & Defense segment, with A$194.99 million from Australia and the rest of the world and A$29.73 million from the USA after eliminations. **Market Cap:** A$2.53b DroneShield is attracting attention because it sits at the centre of a fast maturing counter drone market, moving from one off contract wins to repeat procurement with defence and security customers. Analysts expect both earnings and revenue growth to outpace the broader Australian market. The business has only recently turned profitable and current ROE is low, so execution on its contract pipeline and margin improvement will matter a lot. A recent board and executive refresh, including a new CEO and US leadership, could help scale the business but also adds governance and transition risk, especially with an ASIC inquiry in the background. For investors, the key consideration is whether the combination of strong growth forecasts and expanding use cases outweighs those uncertainties. DroneShield’s shift from one-off wins to repeat defence contracts is only half the story. The real question is whether the growth outlook justifies the risk. Get the full picture in the analyst forecasts for DroneShield ASX:DRO Earnings & Revenue Growth as at Jun 2026 ## IperionX (ASX:IPX) **Overview:** IperionX is a U.S. based critical minerals and advanced materials company that owns 100% of the Titan project in Tennessee, which hosts titanium, zircon and rare earth resources, and also produces titanium metal powders for customers in sectors such as aerospace, defense, automotive, energy and medical devices. **Market Cap:** A$1.48b IperionX catches the eye in this penny stock screen because it combines very early stage revenues with an ambitious plan to build a U.S. critical minerals and titanium manufacturing platform. Forecasts in the market commentary referenced in this screen point to rapid revenue and earnings growth, and recent news around the Titan DFS, U.S. Army testing of titanium fasteners and the acquisition of the Camden silica sand operation all point to a business trying to link high quality resources with downstream titanium products. Against that, current losses, a cash runway of less than 1 year, reliance on higher risk borrowing and a rich P/B multiple mean funding and execution risk are front and centre, especially with limited analyst coverage keeping the full picture harder to see. IperionX’s accelerating titanium ambitions and scarce U.S. critical minerals position are only half the story; the real tension is how funding risk and early revenues collide in the analysis report for IperionX ASX:IPX Earnings & Revenue Growth as at Jun 2026 ## Sigma Healthcare (ASX:SIG) **Overview:** Sigma Healthcare is an Australian pharmacy wholesaler and retail franchisor that supplies medicines to community pharmacies, supports branded pharmacy networks like Chemist Warehouse, Amcal and Discount Drug Stores, and provides logistics and health services, including online retail. **Operations:** Sigma Healthcare generates around A$9.55b in revenue from its Healthcare segment, with about A$9.16b from Australia and A$389.79m from international markets. **Market Cap:** A$31.75b Investors looking at Sigma Healthcare are getting a large scale pharmacy distributor with a long operating history, earnings that analysts expect to grow around the low to mid teens each year, and revenue growth that has been steady rather than spectacular. The company is priced on a high P/E multiple and current profit margins have compressed from 11.5% to 6.3%, so there is pressure on management to turn forecast growth into stronger returns. At the same time, Sigma is backing away from a huge Boots acquisition while still weighing overseas deals. This raises important questions about capital discipline, funding risk and whether its slight discount to estimated fair value fully reflects those trade offs. Compressed margins and a rich P/E suggest Sigma Healthcare’s growth story may not be fully priced in, but the real twist sits in the analyst forecasts for Sigma Healthcare ASX:SIG Earnings & Revenue Growth as at Jun 2026 The three stocks covered here are just a starting sample. The full **Financially Fit Penny Stocks** screen surfaces 391 more companies that match the same balance sheet and cash flow focus as the Financially Fit Penny Stocks screener. Use Simply Wall St to identify and analyze the exact catalysts and narratives that matter to you so you can filter this broader universe down to your highest conviction penny stock ideas. ## Take Control of Your Investment Journey If IperionX or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market. ## Seeking Fresh Alternatives Before They Fly Every breakout move often starts quietly. Momentum can build and prices may move before the broader market pays attention. Scan fresh ideas while they are still under the radar and consider them before they become widely followed. - Explore early breakout momentum across resilient companies by scanning the curated 8 resilient stocks with low risk scores, which highlights ideas that may still show potential while much of the market is focused elsewhere. - Identify fast-moving themes in digital assets before headlines fully reflect them by running the focused 19 cryptocurrency and blockchain stocks and reviewing which stocks are working to build underlying businesses. - Focus on companies involved in AI infrastructure by filtering the curated 49 AI infrastructure stocks to find those working on the hardware and backbone that support this area. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [SIG.AU](https://longbridge.com/en/quote/SIG.AU.md) - [IPX.US](https://longbridge.com/en/quote/IPX.US.md) - [DRO.AU](https://longbridge.com/en/quote/DRO.AU.md) ## Related News & Research - [How New Defense Deals and Clean-Fuel Work Will Impact KBR (KBR) Investors](https://longbridge.com/en/news/296431199.md) - [VisionWave UK names Tony Fabrizio director, aerospace and defense](https://longbridge.com/en/news/296343769.md) - [08:06 ETRK Partners Adds Lieutenant General (Ret.) John Deedrick as Strategic Adviser to Defense Practice](https://longbridge.com/en/news/296352980.md) - [DEFSEC Technologies Raises CAD$5.54 Million in Private Placement to Fund Defense Tech Growth](https://longbridge.com/en/news/296342370.md) - [Defsec publishes investor presentation outlining defence digitization, Lightning SaaS growth strategy](https://longbridge.com/en/news/296363691.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**